Corcept Therapeutics valuation
Valuation
The P/E ratio is 190.2. The average price target of 5 analysts is $141.00.
Data as of November 16, 2026
Corcept Therapeutics compared with similar companies
Corcept Therapeutics's P/E (trailing 12 months): 190.2, +175% against the median of a group of 6 similar companies (69.1).
| Metric | Corcept Therapeutics | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| P/E (trailing 12 months) | 190.2 | 69.1 | 45.4 – 128.0 | High |
| Forward P/E | 16.5 | 15.7 | 9.12 – 24.0 | Middle |
| EV/EBITDA | 64.8 | 16.1 | 12.5 – 30.5 | High |
| Price/book | 18.1 | 15.7 | 5.28 – 18.1 | Middle |
| Price/sales | 15.4 | 8.41 | 6.66 – 15.9 | Middle |
| Gross margin | 98.3% | 91.0% | 59.7% – 95.3% | High |
| Operating margin | 0.8% | 0.8% | -19.7% – 24.5% | Middle |
| Net margin | 6.6% | 0.0% | -5.7% – 10.3% | Middle |
| ROE | 8.2% | 8.2% | -9.7% – 38.5% | Middle |
| Debt/equity | 0.01 | 0.12 | 0.02 – 0.62 | Low |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Corcept Therapeutics: valuation over time
On the latest fiscal year's earnings (2025), Corcept Therapeutics's P/E today is 86.7, above the median of its last 10 fiscal years (27.1; between 15.7 and 103.7 from 2016 to 2025). Relative to earnings, the stock costs more than it used to.
| Fiscal year | Price at year end | Earnings per share | P/E |
|---|---|---|---|
| 2025 | $34.80 | $0.82 | 42.4 |
| 2024 | $50.39 | $1.23 | 41.0 |
| 2023 | $32.48 | $0.94 | 34.6 |
| 2022 | $20.31 | $0.87 | 23.3 |
| 2021 | $19.80 | $0.89 | 22.2 |
| 2020 | $26.16 | $0.85 | 30.8 |
| 2019 | $12.10 | $0.77 | 15.7 |
| 2018 | $13.36 | $0.60 | 22.3 |
| 2017 | $18.06 | $1.04 | 17.4 |
| 2016 | $7.26 | $0.07 | 103.7 |
TickerLandia calculation: closing price on the last trading day of the fiscal year divided by diluted earnings per share from the annual report (positive earnings only). Prices adjusted for splits. Today's P/E is today's price divided by the latest fiscal year's earnings per share, so it compares with the years above.
TickerLandia analysisHow it is calculated
Other metrics
Valuation multiples
- Market cap
- $9.36B
- Enterprise value
- $7.33B
- EV/revenue
- 7.61
Profitability and growth
- ROA
- 0.5%
- ROIC
- 0.6%
- Revenue growth (year over year)
- 31.7%
- Earnings growth (year over year)
- 24.1%
Financial health
- Total debt
- $8.99M
- Current ratio
- 2.86
- Quick ratio
- 2.50
- Altman Z-Score
- 25.6
- Piotroski F-Score
- 6.00
Analysts and estimates
- Average price target
- $141.00
- High price target
- $165.00
- Low price target
- $50.00
- Analysts with a price target
- 5
- Consensus
- Buy
Shares and trading
- Beta
- 0.46
- Average volume
- 1.23M
- Shares outstanding
- 109.44M
- Float
- 97.82M
- Institutional ownership
- 76.8%
- Insider ownership
- 10.5%
- Short interest (% of float)
- 9.3%
- Short ratio (days)
- 9.81
